PubMed · 1996 · 262 citations · 14 references
MedicineNuclear MedicineRadiologyBiomedical ImagingDiagnostic ImagingDiagnostic RadiologyBody ImagingMuscle Mass AssessmentPositron Emission TomographyTumor CharacterizationTumor DetectionTumor ImagingBackprojectionFiltered Back ProjectionMyocardial Tracer Uptake AssessmentMyocardial Uptake QuantificationPet QuantificationQuantitative Uptake MeasurementRegional Uptake AnalysisUptake Pattern Analysis
UNLABELLED: The purpose of this study was to semiquantitatively identify artifactual and physiological soft-tissue accumulations in whole-body FDG-PET scans with the aim of defining their frequency and anatomic distribution. METHODS: Fifty whole-body FDG-PET scans performed for the staging of malignant melanoma were obtained from transaxial scans and reconstructed without absorption correction by filtered backprojection in the form of coronal and sagittal sections. The patients were asked to stay n.p.o. for at least 4 hr and interrogated about their physical activity prior to injection and until scanning. Classification of FDG organ accumulations was done using grades 0-6. Means and standard deviations on this scale were then calculated for multiple organs and muscle groups and tabulated. RESULTS: On this grading scale, viscera showed uptake grades between 1.7 +/- 0.5 and 2.05 +/- 1.0. Except for the intestines, the activity in these organs was homogeneously distributed. Relatively high average uptake values of 2.0-4.2 (s.d. > or = 2.3) were found in various muscle groups, especially the orbital musculature. Myocardial uptake was visible in 90% of the scans. Reconstruction artifacts were seen around the renal collecting system and the bladder. CONCLUSION: Most of the "normal" accumulations of FDG in nonattenuation corrected whole-body PET are readily recognized and distinct from the usually focal FDG accumulation associated with metastatic disease, but the diagnostician must be familiar with them. Muscular FDG uptake is related to physical activity prior and immediately following injection and can be minimized by proper patient instructions and positioning.
14
The applications of PET in clinical oncology.
Ludwig G. Strauss, Peter S. Conti · PubMed · 1991 · 855 citations
Medicine, Nuclear Medicine, Oncology +17
A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)
P. Som, Harold Atkins, D. Bandoypadhyay et al. · Journal of Computer Assisted Tomography · 1980 · 503 citations
Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.
Joel S. Newman, Isaac R. Francis, Mark Kaminski et al. · Radiology · 1994 · 267 citations